Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATG-200
- Development stage
- Preclinical
- Lead developer
- Ategenos Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
ATG-200 is an investigational transdermal drug delivery system developed by Ategenos Pharmaceuticals for behavioral health indications. It utilizes the proprietary SmartPatch technology to deliver an existing, previously approved branded therapy. The system is distinguished by its integrated real-time adherence monitoring capabilities, which allow healthcare providers to track patient compliance and patch performance. By combining a proven therapeutic agent with a digital health delivery platform, ATG-200 aims to overcome common challenges in behavioral health treatment, such as medication non-compliance and inconsistent dosing.
Beyond the preview
Go deeper on ATG-200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATG-200.